Merck & Co (MRK) Q1 2025 Earnings Call April 24, 2025 04:19 PM ET Company Participants Peter Dannenbaum - Senior VP of Investor RelationsRobert Davis - Chairman & CEOCaroline Litchfield - Executive VP & CFODean Li - EVP & President;, Merck Research LaboratoriesGeoff Meacham - Managing DirectorLuisa Hector - Head of Global Pharma Equity ResearchChris Schott - Managing DirectorJames Shin - Director of Biopharma Equity ResearchAlexandria Hammond - Director, Head of TherapeuticsUmer Raffat - Senior Managing Dir ...

For the quarter ended March 2025, Merck (MRK) reported revenue of $15.53 billion, down 1.6% over the same period last year. EPS came in at $2.22, compared to $2.07 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $15.39 billion, representing a surprise of +0.93%. The company delivered an EPS surprise of +3.26%, with the consensus EPS estimate being $2.15.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they co ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, The ...

Pharmaceutical giant Merck & Co Inc (NYSE:MRK) has reversed its premarket lead, down 2% at $77.20 at last glance. The company posted better-than-expected first-quarter results but cut its profit outlook, expecting a $200 million dent from tariffs. Creeping back down toward its April 16 three-year low of $75.95, MRK is down 22.7% since the start of the year. So far today, MRK has seen 21,000 calls and 29,000 puts exchanged -- triple the overall options volume typically seen at this point. The May 75 put is t ...

Exhibit 99.1 News Release Merck Announces First-Quarter 2025 Financial Results RAHWAY, N.J., April 24, 2025 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2025. "Our company made strong progress to start the year, with increasing contributions from our newer commercialized medicines and vaccines and continued advancement of our pipeline," said Robert M. Davis, chairman and chief executive officer, Merck. "We are working with ...

Core Viewpoint - Merck has lowered its full-year profit guidance due to estimated costs from tariffs and a one-time charge related to a recent deal, impacting its adjusted earnings outlook for 2025 [1][4]. Financial Guidance - The company now expects adjusted earnings for 2025 to be between $8.82 and $8.97 per share, a decrease from the previous range of $8.88 to $9.03 per share [1]. - Merck reiterated its full-year sales forecast of between $64.1 billion and $65.6 billion [4]. Tariff Impact - The expected tariff charge is primarily due to levies between the U.S. and China, with additional impacts from Canada and Mexico [2]. - The new outlook does not include the potential effects of President Trump's planned tariffs on pharmaceuticals imported into the U.S., which may lead to increased U.S. manufacturing investments by drugmakers [3]. Investment in U.S. Manufacturing - Merck has invested $12 billion in U.S. manufacturing and research and development, with plans to invest an additional $9 billion by the end of 2028 [3]. Recent Financial Performance - In the first quarter, Merck reported net income of $5.08 billion, or $2.01 per share, compared to $4.76 billion, or $1.87 per share, in the same period last year [6]. - The company earned $2.22 per share excluding acquisition and restructuring costs, surpassing the expected $2.14 [8]. Revenue Performance - Merck's revenue for the first quarter was $15.53 billion, a 2% decrease from the same period a year ago, but above the expected $15.31 billion [7][8]. Product Contributions - The company noted significant sales contributions from two recently launched drugs, Winrevair and Capvaxive, which are expected to help offset losses from its top-selling cancer therapy, Keytruda, set to lose exclusivity in 2028 [5].

一次性使用细胞生物反应器和发酵罐是专用的生物处理设备，设计用于在一次性使用配置中培养细胞或发酵微生物。就一次性使用 细胞生物反应器而言，它们为哺乳动物、微生物或植物细胞的生长提供了受控环境，使单克隆抗体、重组蛋白和疫苗等生物制药的 生产成为可能。同样，一次性发酵罐也用于细菌、酵母或其他微生物的生长，以生产包括酶、生物燃料和有机酸在内的多种产品。 这些一次性使用系统通常由塑料薄膜或硬质聚合物等材料制成的一次性生物反应器或发酵容器，以及用于控制温度、 pH 值、溶解 氧和搅拌等参数的集成传感器和端口组成。它们无需在批次之间进行耗时且成本高昂的清洗和灭菌程序，从而降低了交叉污染的风 险，加快了整个生产流程。因此，它们非常适用于对产品快速转换、灵活性和减少停机时间要求极高的应用领域，如研发、小规模 生产和个性化药品生产等。 一次性使用细胞生物反应器和发酵器全球市场总体规模 据 QYResearch 调研团队最新报告"全球一次性使用细胞生物反应器和发酵器市场报告 2025-2031 "显示，预计 2031 年全球一次性使 用细胞生物反应器和发酵器市场规模将达到 13.2 亿美元，未来几年年复合增长率 CAGR 为 8. ...

Industry Overview - The cancer market is experiencing significant growth due to rising demand for targeted and less toxic cancer medicines, with new cancer cases in the U.S. expected to exceed 2 million for the first time in 2024, leading to increased global spending on cancer treatments [1][3] - Innovative cancer treatments such as immunotherapy, targeted therapies, and personalized vaccines are emerging, utilizing the body's immune system and focusing on specific genetic mutations to provide more effective and less harmful alternatives to traditional chemotherapy [2][3] Company Developments - Major pharmaceutical companies like Novartis, AstraZeneca, Pfizer, AbbVie, and Eli Lilly are actively developing new cancer therapies, including antibody-drug conjugates and immune-oncology agents, while smaller biotech firms are also making significant advancements [4] - Verastem Oncology is seeking FDA approval for its combination regimen of avutometinib and defactinib for treating KRAS mutant recurrent low-grade serous ovarian cancer, with a decision expected by June 30, 2025 [6][7] - Relay Therapeutics has reported positive interim data for its RLY-2608 breast cancer program, leading to plans for a pivotal study in mid-2025 [9][10] - Pyxis Oncology is focused on developing next-generation therapeutics, with its lead candidate showing significant tumor regression in patients with recurrent and metastatic head and neck squamous cell carcinoma, and has received Fast Track Designation from the FDA [12][13][14]

报名：首届全球眼科大会 | 议程更新 报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 合作伙伴征集：2025全球手术机器人大会 近日，生命科学公司Caris Life Sciences宣布，已完成一轮 1.68亿美元(合约12.2亿人民币) 的融资，以 支持其精准医疗平台的发展。 此次融资由投资者 Braidwell 领投，Perceptive Advisors、Woodline、Ghisallo、Millennium Management 和 First Light Asset Management 等也参与了投资。此轮融资使 Caris Life Sciences 自 2018 年以来的总筹资额达到 18.6 亿美元(合约135.98亿人民币) # 核心业务 Caris Life Sciences 成立于2008年， 公司致力于通过分子分析和人工智能技术，为癌症及其他复杂疾 病患者提供精准的诊断和治疗方案。 physician tests 业务 包括组织分析、血液分析以及人工智能相关服务。 分子分析技术： MI Profile™， 用于评估肿瘤组织中的 DNA、RNA 和蛋白 ...

特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 导读： 当地时间 2025年4月9日，美国对部分中国输美商品累计税率高达104%的 "核弹级"政策正式落地 。 本期 《 视角 》 栏目我们 来聊聊这波猝不及防的"战事"。 据白宫官网公告，美国对中国征收1 0 4%关税将在当地时间周三（4月1 0日）凌晨1 2 : 0 1起生效，并上调了价值8 0 0美元 或以下商品所需缴纳的税额。 迅速恶化的"战况" 这场被专家称为" 2 1世纪最大规模贸易战"的博弈始于2 0 2 5年4月3日， 美国总统特朗普在白宫签署了关于"对等关税"的 行政令， 宣布对所有贸易伙伴设立1 0%的"最低基准关税"，并对部分经济体征收更高税率。亚洲国家成为"重灾区"， 其中 对中国的关税加征幅度高达3 4% 。 此后，事情的发展速度令人始料未及： · 北 京 时 间 4 月 4 日 ， 中 国 国 务 院 关 税 税 则 委 员 会 、 商 务 部 、 海 关 总 署 相 继 出 台 一 系 列 对 美 反 制 措 施 ， 强 硬 " 奉 陪 到 底"。措施内容 ...